Retina Forum® 2021: Meeting the Vision of Reduced Treatment Burden in Neovascular Retinal Diseases - Session on Extending the Duration of Therapy

1.00 CME
1.00 CME with ABO CC
$0 FEE
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

Retina Forum® 2021: Meeting the Vision of Reduced Treatment Burden in Neovascular Retinal Diseases - Session on Extending the Duration of Therapy


Provider Statement

This continuing medical education activity is provided by Vindico Medical Education

Support Statement

This activity is supported by an educational grant from Genentech, Inc.

Activity Description

Treatment burden and subsequent loss of patient adherence are significant factors associated with less-than-optimal visual acuity gains seen in real-world outcomes in patients with neovascular retinal diseases. Ongoing clinical studies are evaluating novel delivery systems, gene therapies, and agents that enhance dosing intervals while targeting novel pathways with the potential to reduce treatment burden and improve visual acuity outcomes. In this educational activity, Meeting the Vision of Reduced Treatment Burden in Neovascular Retinal Diseases – Session on Extending the Duration of Therapy, experts in the field review the treatment burden observed with current therapies; examine the role of persistent retinal fluid in determining response to treatment; as well as evaluate new and emerging agents that may reduce the burden of anti-vascular endothelial growth factor (VEGF) therapy in neovascular retinal diseases.

Target Audience

The intended audience for this activity is comprehensive ophthalmologists, retinal specialists, and other health care professionals involved in the management of patients with retinal diseases.

Learning Objectives

Upon successful completion of this activity, participants should be better able to:

  • Review the burden associated with current therapies used for the treatment of neovascular retinal diseases.
  • Assess the long-term effects of anti-VEGF therapy on vision, the potential for complications, and patient outcomes.
  • Summarize the evidence demonstrated in major clinical trials regarding treatment protocols and their application to real-world practice in the treatment of neovascular retinal diseases.
  • Examine the role of persistent retinal fluid in determining response to treatment in neovascular retinal diseases.
  • Evaluate new and emerging modalities that may reduce the burden of anti-VEGF therapy in neovascular retinal diseases.

Activity Chair

Rishi P. Singh, MD
Staff Physician, Cole Eye Institute
Medical Director, Clinical Systems Office
Cleveland Clinic
Associate Professor of Ophthalmology
Case Western Reserve University
Cleveland, OH


Nancy M. Holekamp, MD
Director, Retina Services
Pepose Vision Institute
Professor of Clinical Ophthalmology
Washington University School of Medicine 2009-2020
St. Louis, MO

Michael A. Singer, MD
Director of Clinical Research
Medical Center Ophthalmology Associates
Clinical Professor
University of Texas Health Science Center
San Antonio, TX


Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP


Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation

Vindico Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to satisfy the Lifelong Learning and Self-Assessment requirements for the American Board of Ophthalmology’s Continuing Certification program. It is the CME activity provider’s responsibility to submit learner completion information to ACCME for the purpose of granting credit.

Upon successful completion, learners who opt-in by providing their ABO ID and DOB (MM/DD) will earn credits equivalent to the amount of CME credits claimed for the activity.

This enduring material is approved for 1 year from the date of original release, April 30, 2021, to April 29, 2022.

How to Participate in This Activity and Obtain CME Credit

To participate in this CME activity, you must read the objectives, answer the polling and pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 3 of the 4 posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ certificate.


In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. Individuals have a relevant financial relationship if they have a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information appears below.  

Activity Chair and Faculty report the following relationship(s)

Nancy M. Holekamp, MD
Intellectual Property/Patent: Katalyst Surgical
Consulting Fee: Adverum, Allergan, Apellis, Bayer, Clearside, Gemini, Genentech, Gyroscope, Katalyst Surgical, Lineage Cell Therapeutics, Nacuity, Notal Vision, Novartis, PolyActiva, Regeneron
Speakers Bureau: Allergan, Genentech, Novartis, Regeneron, Spark
Contracted Research: Gemini, Genentech, Gyroscope, Notal Vision, Regeneron

Michael A. Singer, MD
Consulting Fee: Aerie, Allegro, Allergan, EyePoint, Genentech, Novartis, Regeneron
Speakers Bureau: Allergan, Genentech, Mallinckrodt, Novartis, Regeneron, Spark
Contracted Research: Aerie, Allegro, Allergan, Chengdu Kanghong, DRCR, Genentech, Icon, Ionis, Iveric Bio, KalVista, Kodiak, Novartis, Opthea, Optos, Regeneron, Ribomic, Santen, Senju, Sydnexis, Xplore

Rishi P. Singh, MD
Consulting Fee: Alcon, Apellis, Genentech, Gyroscope, Novartis, Regeneron, Zeiss
Contracted Research: Aerie, Apellis, Graybug

Reviewer reports the following relationship(s)

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.

Vindico Medical Education staff report the following relationship(s)

No relevant financial relationships to disclose.

Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)–approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at